Gefitinib is primarily used for treating NSCLC, particularly in patients who have specific mutations in the EGFR gene. These mutations make the cancer cells more susceptible to the effects of gefitinib. Histologically, NSCLC with these mutations often shows a specific pattern that includes glandular differentiation and mucin production.
